Epilepsy Res. 2025 Nov 15;219:107694. doi: 10.1016/j.eplepsyres.2025.107694. Online ahead of print.

ABSTRACT

OBJECTIVE: We systematically reviewed the existing literature on the efficacy of the ketogenic diet (KD) in patients with epileptic spasms (ES) and analyzed predictors of seizure outcomes.

METHODS: The Preferred Report Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed. The primary outcome was the proportion of patients achieving 50-99 % spasm reduction at 3 months following KD initiation. Additional outcomes included the proportion of patients achieving complete spasm freedom at 1, 3, and 6 months. Meta-regression was employed to examine clinical determinants of seizure outcomes.

RESULTS: Twenty-two studies (n = 1077 individuals) were included. There were 607 males (62.2 %) and 369 females (37.8 %) (k = 16 studies). The mean age of KD initiation was 16 months (SD: 5.4, range: 8.4-23 months) (k = 11 studies). Epilepsy etiology was reported in 453 individuals (k = 15 studies), 297 (65.6 %) had a known etiology and 156 (34.4 %) were unknown. Structural (n = 178, 59.9 %) and genetic/metabolic (n = 80, 26.9 %) causes were common. Most received the classic ketogenic diet (n = 975/1077, 90.5 %) and 102 patients (9.5 %) received the modified Atkins diet (MAD). At 3 months, 48 % (95 % CI: 40 %, 57 %) achieved a 50-99 % spasm reduction and 25 % (95 % CI: 17 %, 34 %), achieved spasm freedom. At 6 months, 41 % (95 % CI: 32 %, 50 %) achieved 50-99 % spasm reduction and 25 % (95 % CI: 17 %,35 %), achieved spasm freedom. Meta-regression did not identify predictors of treatment response.

CONCLUSION: KD may be an effective treatment option for ES. However, predictors of clinical response were not identified, highlighting the need for larger studies to better understand them and long-term outcomes.

PMID:41252815 | DOI:10.1016/j.eplepsyres.2025.107694

From ketogenic via this RSS feed